Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$22.21 - $34.48 $205,886 - $319,629
-9,270 Reduced 30.47%
21,151 $687,000
Q1 2024

May 15, 2024

SELL
$21.1 - $27.46 $164,347 - $213,885
-7,789 Reduced 20.38%
30,421 $766,000
Q4 2023

Feb 14, 2024

BUY
$24.82 - $32.88 $330,676 - $438,060
13,323 Added 53.53%
38,210 $1.24 Million
Q3 2023

Nov 14, 2023

BUY
$21.97 - $33.8 $103,346 - $158,995
4,704 Added 23.31%
24,887 $678,000
Q1 2023

May 15, 2023

SELL
$19.2 - $24.47 $75,648 - $96,411
-3,940 Reduced 16.33%
20,183 $437,000
Q4 2022

Feb 14, 2023

BUY
$19.95 - $29.96 $481,253 - $722,725
24,123 New
24,123 $489,000
Q3 2020

Nov 16, 2020

SELL
$12.46 - $19.98 $134,655 - $215,923
-10,807 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$10.11 - $14.04 $109,258 - $151,730
10,807 New
10,807 $128,000
Q1 2018

May 15, 2018

SELL
$14.59 - $25.5 $238,677 - $417,154
-16,359 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$15.77 - $20.72 $257,981 - $338,958
16,359
16,359 $295,000

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $5.51B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Petrus Trust Company, Lta Portfolio

Follow Petrus Trust Company, Lta and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Petrus Trust Company, Lta, based on Form 13F filings with the SEC.

News

Stay updated on Petrus Trust Company, Lta with notifications on news.